Volume 7, Issue 1 (3-2021)
CJP 2021, 7(1): 0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Haghshenas Mojaveri M, Rasoulinejad S A. Red blood cell indexes and laboratory findings in stage III of retinopathy of prematurity. CJP 2021; 7 (1) :495-501
URL: http://caspianjp.ir/article-1-156-en.html
URL: http://caspianjp.ir/article-1-156-en.html
Department of Ophthalmology, Ayatollah Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran , a.rasoulinejad@mubabol.ac.ir
Abstract: (2371 Views)
Background and Objective: Retinopathy of prematurity (ROP) is a progressive neovascular retinal disorder in neonates. This study investigated the possible correlation of hematological and biochemical laboratory indexes with the plus disease and the neovascularization of the iris (NVI) statuses in stage III ROP patients.
Methods: This case-control study was performed on 124 stages III ROP patients [(a) 58 cases with plus disease and 66 cases without plus disease, (b) 7 cases with NVI and 117 cases without NVI] in the Ophthalmology center of Ayatollah Rouhani Hospital, Babol, Iran. All ophthalmologic examinations were performed according to the international classification of retinopathy of prematurity (ICROP) criteria. The hematopoietic/biochemical parameters, i.e., WBC, Hb, Plt, Na, K, Ca, CRP, T4, TSH, PCO2, PO2, HCO3, SpO2, MCV, and MCH, were evaluated based on standard protocols.
Findings: The MCV in patients with and without plus disease were 84.88±22.274 and 94.12±14.419 fl/cell in ROP patients, respectively; (p=0.012). Also, the MCH in patients with and without the plus disease were 30.12±3.649 and 31.99±5.149 pg/cell, respectively (p =0.033). Our results showed that CRP is higher in patients with plus disease (16.11±29.403 mg/L) than patients without plus disease (3.25±2.633 mg/dl); (p=0.033). Also, SpO2 was significantly higher in stage III ROP patients with NVI (64.00±13.730%) compared to non-NVI patients (75.58±16.135%); (p=0.043).
Conclusion: NVI and plus disease statuses in stage III ROP are associated with CRP, SpO2, MCV, and MCH. It may be related to dysregulated hematopoiesis or transfusion. Other studies are recommended to investigate these associations.
Methods: This case-control study was performed on 124 stages III ROP patients [(a) 58 cases with plus disease and 66 cases without plus disease, (b) 7 cases with NVI and 117 cases without NVI] in the Ophthalmology center of Ayatollah Rouhani Hospital, Babol, Iran. All ophthalmologic examinations were performed according to the international classification of retinopathy of prematurity (ICROP) criteria. The hematopoietic/biochemical parameters, i.e., WBC, Hb, Plt, Na, K, Ca, CRP, T4, TSH, PCO2, PO2, HCO3, SpO2, MCV, and MCH, were evaluated based on standard protocols.
Findings: The MCV in patients with and without plus disease were 84.88±22.274 and 94.12±14.419 fl/cell in ROP patients, respectively; (p=0.012). Also, the MCH in patients with and without the plus disease were 30.12±3.649 and 31.99±5.149 pg/cell, respectively (p =0.033). Our results showed that CRP is higher in patients with plus disease (16.11±29.403 mg/L) than patients without plus disease (3.25±2.633 mg/dl); (p=0.033). Also, SpO2 was significantly higher in stage III ROP patients with NVI (64.00±13.730%) compared to non-NVI patients (75.58±16.135%); (p=0.043).
Conclusion: NVI and plus disease statuses in stage III ROP are associated with CRP, SpO2, MCV, and MCH. It may be related to dysregulated hematopoiesis or transfusion. Other studies are recommended to investigate these associations.
Keywords: Bevacizumab, Retinal Neovascularization, Retinopathy of Prematurity, Vascular Endothelial Growth Factors
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
